Phase 2
N=30
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
Pediatric Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05148078 ↗Enrolled (actual)
30
Serious AEs
—
Results posted
Mar 2026
Primary outcome: Primary: Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments — 88; 12 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect) (Other)
- Age
- Pediatric · 3+ yrs
- Sex
- All
- Sponsor
- University of Texas Southwestern Medical Center
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Pediatric Patients Age 3-7 Who Require Daily General Anesthesia for All Treatments |
88; 12 | — |
| SECONDARY Patient- and Family-reported Health Quality of Life (QOL) |
66.27; 77.07; 75.32; 72.50; 76.77; 78.92 | — |
| SECONDARY Patient Reported Anxiety by Family |
29.19; 23.55 | — |
| SECONDARY Patient Movement |
1.34 | — |
Summary
PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect) is an interactive incentive-based movie system that integrates with a video surveillance gating module (VisionRT) as an alternative sedation solution for pediatric patients undergoing radiation treatment (RT). This single-arm, open label, single-center phase II clinical trial is to implement PROMISE for all children ages 3-11 who are planned to undergo RT at the institution. The primary goal is to decrease the total number of pediatric patients who require general anesthesia through the use of PROMISE, with secondary goals being to assess the impact that PROMISE has on patient/family anxiety and quality of life, treatment time and clinical efficiency, and overall cost. The investigators hypothesize that PROMISE will lead to a reduction in the percentage of patients ages 3-7 who require general anesthesia use from 70% (historical control) to 30%.
Eligibility Criteria
Inclusion Criteria
- Planned to undergo radiation treatment
- Age 3-11 years
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at screening
- Parents or guardians with the ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
- Subjects with documented medical behavior conditions or other conditions necessitating anesthesia use
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
- Subjects whose parents opt to not include them (the subject) in the clinical trial.
Data sourced from ClinicalTrials.gov (NCT05148078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.